Pfizer (NYSE:PFE) announced today that it entered into a multi-year agreement with Gilead Sciences (NSDQ:GILD) to manufacture and supply its antiviral remdesivir treatment.
The investigational antiviral remdesivir will be manufactured by Pfizer under the agreement as the company becomes one of the multiple external manufacturing organizations supporting efforts to scale up the supply of the investigational treatment for COVID-19. Pfizer will offer contract manufacturing services at its McPherson, Kan.-based facility to supply remdesivir for Gilead.
Get the full story at our sister site, Pharmaceutical Processing World.